Geptanolimab shows efficacy in relapsed/refractory peripheral T-cell lymphoma

Geptanolimab, an anti-PD-1 antibody, appeared effective and safe for patients with relapsed or refractory peripheral T-cell lymphoma, according to results of a phase 2 multicenter trial presented at the virtual American Association for Cancer Research Annual Meeting.